Dr Sarah Bohndiek awarded the CRUK Future Leaders Prize
Dr Sarah Bohndiek has been awarded the Cancer Research UK Future Leaders Prize at this week’s National Cancer Research Institute (NCRI) Conference in Glasgow.
The Future Leaders Prize celebrates early career scientists who have demonstrated the potential to achieve world-leading status by producing research of international importance. The prize is awarded annually to up to three outstanding cancer researchers nominated by their peers and selected by an international panel.
Dr Bohndiek’s work focuses on developing new imaging tools to study the development and evolution of cancer based on low cost optics and photonics technologies. The Group apply new imaging methods in cancer models to explore the role of the tumour microenvironment in cancer development and are active in the translation of these methods into the clinic. She became a Group Leader at the Cancer Research UK Cambridge Institute in 2014 and a Reader in Biomedical Physics in 2017.

Dr Sarah Bohndiek also co-leads the Cancer Research UK Cambridge Centre’s Early Detection Programme with Prof Rebecca Fitzgerald, who received the Jane Wardle Prize at the same event. The prize recognises an individual who has produced world-leading research in the field of prevention and early detection of cancer. Prof Fitzgerald is a Programme Leader at the MRC Cancer Unit whose work focuses on the need to identify patients at a high risk for cancer of the oesophagus so they can be prevented from developing the disease.
Related News
See all news-
New immune pathway offers treatment hope for childhood brain tumours
3rd February 2026
A newly discovered immune pathway could lead to gentler treatments for multiple childhood brain cancers, according to new research from our Gilbertson Group published today in Nature Genetics.
Find out more -
Targeting paused cells could improve chemotherapy for lung and ovarian cancers
3rd February 2026
New research published today in Nature Aging by scientists at the University of Cambridge sheds light on why some lung and ovarian cancers stop responding to chemotherapy, and how this resistance might one day be prevented.
Find out more -
Hot flush treatment has anti-breast cancer activity, study finds
5th January 2026
A drug mimicking the hormone progesterone has anti-cancer activity when used together with conventional anti-oestrogen treatment for women with breast cancer, a new Cambridge-led trial has found.
Find out more